Clinical Trial Update: Cabozantinib for Advanced Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of cabozantinib in advanced urothelial cancer has completed and results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Neoplasms
• Urinary Bladder Neoplasms
• Urothelial Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Urothelial Carcinoma, Urethral Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-10-06